Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Group 0103

Clinical Colorectal Cancer

Volumn 3, Issue 3, 2003, Pages 186-189

  Comella, Pasquale ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant therapy; Combination chemotherapy; Diarrhea; Neuropathy; Neutropenia

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; METHOTREXATE; OXALIPLATIN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; ITALY; METASTASIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

EID: 0347600576     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2003.n.025     Document Type: Article

References (20)

1. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-715.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
4. Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002; 13:866-873.
5. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071.
6. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739-2744.
7. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998; 9:105-108.
8. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
9. Taron M, Plasencia C, Abad A, et al. Preclinical synergy of oxaliplatin (OXA), topoisomerase I-inhibitor (topotecan) and 5-fluorouracil in sensitive and 5-fluorouracil resistant HT29 cell line. Proc Am Soc Clin Oncol 1999; 18:170a (Abstract #651).
10. Fischel JL, Etienne MC, Formento P, et al. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 1998; 4:2529-2535.
11. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
12. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
13. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17:3560-3568.
14. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001; 37:1000-1005.
15. Zori Comba A, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37:1006-1013.
16. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002; 20:2545-2550.
17. Vassilaki M, Desses N, Parassiris V, et al. Two phase II studies with the combination of oxaliplatin/(L-OHP) + 5-fluorouracil (5-FU) + leucovorin (LV) as first line treatment in PTS with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 2000; 19:284a (Abstract #1111).
18. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
19. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893-900.
20. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics 1989; 45:537-547.